Abstract:Introduction: G protein-coupled receptor (GPR) 40 is abundantly expressed in β cells. GPR40 and GPR120 are also expressed on the intestinal L cells and activating GPR40 and GPR120 can stimulate L cells to secret glucagon like peptide (GLP)-1. GW 9508 is a small-molecule agonist of GPR40 and GPR120. It dose dependently potentiates glucose-stimulated insulin secretion. In this study, we investigated whether GW9508 can directly stimulate β-cell replication in vitro and in vivo and improve islet graft function in diabetic mice. Methods: To determine β-cell proliferation in vitro, C57BL/6 mouse islets were cultured for 4 days, with and without GW9508. BrdU was added on day 3 for overnight. Insulin and BrdU immunofluorescence staining was performed on intact islets. Insulin+ and BrdU+ β cells were accounted using confocal microscope. To determine islet graft function, 100 C57BL/6 mouse islets were transplanted under the left kidney of each streptozotocin induced-diabetic C57BL/6 mouse. Recipient mice were orally treated with vehicle for GW9508 (containing dimethyl sulfoxide) or with GW9508 at 10 mg/kg/day, starting from the day of islet transplantation. All recipient mice were also intraperitoneally treated with BrdU at 100 mg/kg/day to label the replicated cells. Islet graft function was monitored by measuring blood glucose level. At 4 weeks, left nephrectomy was performed to remove the kidney bearing islet grafts to determine β-cell replication in islet grafts. Results: Insulin+ and BrdU+ β cells in each cultured islet were 13.6±1.2 cells with 0.1 μM GW9508; 18.3±1.5 cells with 1 μM GW9508; and 27.4±2.4 cells with 10 μM GW9508 (P< 0.01, vs. 10.5±0.6 cells in each untreated islet). At 2 week after islet transplantation, normoglycemia was achieved in 50% vehicle-treated mice achieved (n=10) and 100% GW9508-treated mice achieved normoglycemia (n=10). Although all recipient mice achieved normoglycemia at 4 weeks with or without treatment, normoglycemia was achieved in significantly fewer days in GW9508-treated mice. The vehicle-treated mice achieved normoglycemia in 14.4 ±2.9 days, while GW9508-treated mice only required 6.4±2.9 days (P< 0.01). The percentage of insulin+ and BrdU+ β cells in islet grafts were significantly higher in GW9508-treated mice than in vehicle-treated mice. The mean percentage of insulin+ and BrdU+ β cells in islet grafts was 23.6±6.4% in GW9508-treated mice and 6.7±3.4% in vehicle-treated mice (P< 0.01). At 30 minutes treatment, plasma GLP-1 was 9.3±2.6 pM/L in vehicle-treated mice and 14.7±4.7 pM/L in GW9508-treated mice (P< 0.05). Conclusion: Our data demonstrated that GW9508 can stimulate β-cell replication and improve islet graft function. Targeting GPR40 and/or GPR120 is a new therapeutic approach to stimulate β-cell replication and to improve islet graft function.

Stimulating Beta Cell Replication and Improving Islet Graft Function by A Gpr40 and Gpr120 Dual Agonist